Amarin Corp Plc (AMRN)

[HDGabor]

Commitment to the R-IT does not mean anything, other than they do not have a choice.

From a purely fiscal perspective:
- it had not been an option to stop R-IT ever
- R-IT is not for FDA’s favor, it’s for AMRN’s favor

MARINE market only (with current expenditures w/o R-IT cost):
- breakeven is around 20k scripts / week
- if every patient who takes V / L / generic L (85k) takes V: $5M weekly, $260M yearly profit
- PPS (for simplicity with P/E:1 and 200M shares): $1,3

R-IT market (with current expenditures w incremental $253M Selling and Marketing expenditure and w/o R-IT cost, since it was finished):
- breakeven is around 83k scripts / week
- if every patient who takes V / L / generic L / Fenofibrates / Niaspan / Tricor / Trilipix (575k) takes V: $38,5M weekly, $2,000M yearly profit
- PPS (for simplicity with P/E:1 and 200M shares): $10

To finish R-T they need (for simplicity) 200M. If they raise it as a dilution (I do not think it, but assume with $1/shares) it is additional 200M shares:
- PPS (for simplicity with P/E:1 and 400M shares): $5

Hm? $1,3 vs $5? I think it is not a question.